

## Statement of Advice:

### **ceftazidime/avibactam 2g/0.5g powder for concentrate for solution for infusion (Zavicefta®)** **SMC No 1307/18** **Pfizer Ltd**

8 December 2017

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation **ceftazidime/avibactam (Zavicefta®)** is not recommended for use within NHS Scotland.

**Indication under review:** Treatment of the following infections in adults:

- complicated intra-abdominal Infection (cIAI)
- complicated urinary tract infection (cUTI), including pyelonephritis
- hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
- infections due to aerobic Gram-negative organisms in adult patients with limited treatment options

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

#### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman**  
**Scottish Medicines Consortium**